Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report)’s share price gapped up before the market opened on Tuesday after Evercore ISI raised their price target on the stock from $41.00 to $48.00. The stock had previously closed at $26.08, but opened at $27.00. Evercore ISI currently has an outperform rating on the stock. Crinetics Pharmaceuticals […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) saw some unusual options trading activity on Tuesday. Stock traders bought 2,787 put options on the company. This represents an increase of 269% compared to the typical volume of 756 put options. Insider Activity In other news, CFO Marc Wilson sold 30,922 shares of the firm’s stock […]
By Jeffrey T. Lewis Crinetics Pharmaceuticals shares rose 17% a day after they rocketed higher following the announcement of a successful study of a growth.
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) had its price target lifted by analysts at Robert W. Baird from $43.00 to $45.00 in a note issued to investors on Monday, FlyOnTheWall reports. Robert W. Baird’s target price points to a potential upside of 181.78% from the stock’s current price. A number of other analysts also […]
Shares of Crinetics Pharmaceuticals Inc. gained 65% premarket on Monday after the company announced positive results from a late-stage study of paltusotine,.